company background image
ABCL

AbCellera BiologicsNasdaqGS:ABCL Stock Report

Last Price

US$8.64

Market Cap

US$2.4b

7D

-14.0%

1Y

-82.9%

Updated

23 Jan, 2022

Data

Company Financials +
ABCL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

ABCL Stock Overview

AbCellera Biologics Inc. develops antibody discovery platform.

AbCellera Biologics Competitors

10x Genomics

NasdaqGS:TXG

US$10.0b

Adaptive Biotechnologies

NasdaqGS:ADPT

US$2.3b

Berkeley Lights

NasdaqGS:BLI

US$599.9m

AbbVie

NYSE:ABBV

US$233.3b

Price History & Performance

Summary of all time highs, changes and price drops for AbCellera Biologics
Historical stock prices
Current Share PriceUS$8.64
52 Week HighUS$55.22
52 Week LowUS$8.51
Beta0
1 Month Change-42.13%
3 Month Change-47.54%
1 Year Change-82.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.33%

Recent News & Updates

Dec 05

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast. Using a 10% discount rate, I estimate the current value of only the current programs at over $41. This estimate does not include any COVID revenues going forward.

Shareholder Returns

ABCLUS Life SciencesUS Market
7D-14.0%-4.7%-6.1%
1Y-82.9%1.8%4.2%

Return vs Industry: ABCL underperformed the US Life Sciences industry which returned 1.8% over the past year.

Return vs Market: ABCL underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is ABCL's price volatile compared to industry and market?
ABCL volatility
ABCL Average Weekly Movement10.8%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: ABCL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ABCL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012360Carl Hansenhttps://www.abcellera.com

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract.

AbCellera Biologics Fundamentals Summary

How do AbCellera Biologics's earnings and revenue compare to its market cap?
ABCL fundamental statistics
Market CapUS$2.43b
Earnings (TTM)US$177.26m
Revenue (TTM)US$443.78m

13.7x

P/E Ratio

5.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABCL income statement (TTM)
RevenueUS$443.78m
Cost of RevenueUS$104.25m
Gross ProfitUS$339.53m
ExpensesUS$162.27m
EarningsUS$177.26m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.63
Gross Margin76.51%
Net Profit Margin39.94%
Debt/Equity Ratio0.2%

How did ABCL perform over the long term?

See historical performance and comparison

Valuation

Is AbCellera Biologics undervalued compared to its fair value and its price relative to the market?

13.72x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABCL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABCL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABCL is good value based on its PE Ratio (13.7x) compared to the US Life Sciences industry average (39.3x).

PE vs Market: ABCL is good value based on its PE Ratio (13.7x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: ABCL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ABCL is good value based on its PB Ratio (2.6x) compared to the US Life Sciences industry average (3.2x).


Future Growth

How is AbCellera Biologics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-48.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABCL's earnings are forecast to decline over the next 3 years (-48.3% per year).

Earnings vs Market: ABCL's earnings are forecast to decline over the next 3 years (-48.3% per year).

High Growth Earnings: ABCL's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ABCL's revenue is expected to decline over the next 3 years (-12.2% per year).

High Growth Revenue: ABCL's revenue is forecast to decline over the next 3 years (-12.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ABCL is forecast to be unprofitable in 3 years.


Past Performance

How has AbCellera Biologics performed over the past 5 years?

1,459.9%

Last years revenue growth


Earnings and Revenue History

Quality Earnings: ABCL has high quality earnings.

Growing Profit Margin: ABCL became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ABCL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: ABCL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ABCL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).


Return on Equity

High ROE: ABCL's Return on Equity (22.1%) is considered high.


Financial Health

How is AbCellera Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: ABCL's short term assets ($803.7M) exceed its short term liabilities ($49.5M).

Long Term Liabilities: ABCL's short term assets ($803.7M) exceed its long term liabilities ($169.8M).


Debt to Equity History and Analysis

Debt Level: ABCL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ABCL's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: ABCL's debt is well covered by operating cash flow (15491.1%).

Interest Coverage: ABCL's interest payments on its debt are well covered by EBIT (113.4x coverage).


Balance Sheet


Dividend

What is AbCellera Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABCL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABCL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABCL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Carl Hansen (47 yo)

9.17yrs

Tenure

US$16,962,608

Compensation

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD16.96M) is above average for companies of similar size in the US market ($USD5.29M).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ABCL's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: ABCL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ABCL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.


Top Shareholders

Company Information

AbCellera Biologics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AbCellera Biologics Inc.
  • Ticker: ABCL
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.433b
  • Shares outstanding: 281.58m
  • Website: https://www.abcellera.com

Number of Employees


Location

  • AbCellera Biologics Inc.
  • 2215 Yukon Street
  • Vancouver
  • British Columbia
  • V5Y 0A1
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:00
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.